Abstracts tagged "osteoprotegerin and rheumatoid arthritis (RA)"

Abstract Number: 2379 • 2017 ACR/ARHP Annual Meeting
Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Javier Narváez¹, Irene Martin-Esteve², Andrea Zacarias³, Pedro Alia⁴, Estibaliz Loza⁵, Loreto Carmona⁵, Joan Miquel Nolla² and Carmen Gomez Vaquero⁶, ¹Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitari de Bellvitge, Barcelona, Spain, ⁴Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the association between osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and the annual percent change (Δ%) in bone mineral density (BMD) in patients…
Abstract Number: 2461 • 2014 ACR/ARHP Annual Meeting
Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis
Raquel López-Mejías¹, Begoña Ubilla¹, Fernanda Genre¹, Alfonso Corrales¹, José L Hernandez², Ivan Ferraz-Amaro³, Linda Tsang⁴, Javier Llorca⁵, Ricardo Blanco⁶, Carlos González-Juanatey⁷, MA González-Gay^1,4 and Patrick H Dessein⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Department of Internal Medicine, Hospital Universitario Marques de Valdecilla, University of Cantabria, RETICEF, IDIVAL, Santander, Spain, ³Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ⁴Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain
Background/Purpose: We determined whether osteoprotegerin (OPG) concentrations are associated with established cardiovascular disease (CVD) amongst patients with rheumatoid arthritis (RA). Methods: OPG concentrations were measured…
Abstract Number: 232 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis
Kotaro Shikano, Kaichi Kaneko, Mai Kawazoe, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is known as a cause of secondary osteoporosis. The previous studies reported that receptor activator for nuclear factor κB ligand (RANKL)…
Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Claire I. Daien¹, Anne-Marie Dupuy Gorce², Edith Pinot², Thibault Mura³, Jean-Paul Cristol², Bernard Combe⁴ and Jacques Morel⁵, ¹Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Biochemistry, Hopital Lapeyronie, Montpellier, France, ³CIC, Hopital Gui De Chauliac, Montpellier, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].